company face complex somewhat contradictory information umer raffat analyst investment bank evercore isi asked departure michael ehlers biogen previous research development chief disagreements alzheimer dataset vounatsos biogen ceo said ehlers departure personal implying disagreement data not play role raffat asked way trial successful failed data low dose groups consistent trials confidence result occurred study study called emerge patients high dose aducanumab 23 reduction rate decline compared placebo low dose 11 lower placebo result not statistically significant second trial engage decrease 2 patients high dose biogen said patients emerge received higher doses changes late studies biogen disclosed data patients completed study